Amgen Inc.

NASDAQ:AMGN

Drug Manufacturers - General

Healthcare
$443.89 -2.03%

-$6.93 today

Market cap
$240.11B
Beta
0.42
P/E (TTM)
23.2
EPS (TTM)
$14.44
Dividend yield
2.93%
52W Low $267.83High $391.29

Volume 2.58M

Average 2.76M

AMGN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Amgen Inc.NASDAQ: AMGN

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 72.0%

Gross margin was 72.0% in Q2 FY2026, up 4.9 pp from a year earlier. On a trailing-twelve-month basis it was 72.7%, up 8.2 pp year over year. Over 3 fiscal years it narrowed by 4.9 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
72.0%+3.9 pp QoQ
Last fiscal yearDec 2025
70.8%+9.3 pp YoY
LTMJun 2026
72.7%+8.2 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+4.9 pp——
1 year+9.3 pp——
3 years-4.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
70.8%
Year-over-year change
+9.3pp

Gross Margin vs competitors

How AMGN compares with its peers on the latest reported figures

  • AMGN's LTM Jun 2026 gross margin of 72.7% is the 8th highest of the 10 companies compared; the peer median is 74.4%.
  • Its year-over-year change of +8.2 pp is the highest of 10, against a peer median of +0.7 pp.
  • Over three fiscal years its change of -4.9 pp compares with a peer median of +1.7 pp.
AMGN Competitors Peer median
Gross Margin for AMGN and competitors
Company Period LTM level YoY 3-year change
LLYEli Lilly and CompanyLTM Jun 202683.4% +0.8 pp+6.3 pp
AZNAstraZeneca PLCLTM Sep 202680.1% -2.3 pp+9.8 pp
ABBVAbbVie Inc.LTM Sep 202676.3% +6.5 pp+0.2 pp
MRKMerck & Co., Inc.LTM Jun 202675.4% -0.1 pp+1.3 pp
NVSNovartis AGLTM Jun 202674.4% -1.8 pp+1.7 pp
PFEPfizer Inc.LTM Jun 202673.2% +1.1 pp+8.3 pp
GSKGSK plcLTM Jun 202672.7% +1.4 pp+5.0 pp
AMGNAmgen Inc.LTM Jun 202672.7% +8.2 pp-4.9 pp
BMYBristol-Myers Squibb CompanyLTM Jun 202670.2% -0.1 pp-7.0 pp
JNJJohnson & JohnsonLTM Sep 202668.8% +0.7 pp-1.4 pp
Peer median (excluding AMGN) 74.4%+0.7 pp+1.7 pp

Competitors are the stored peer set for AMGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue25.98B26.32B28.19B33.42B36.74B
Cost of Revenue6.45B6.41B8.42B12.86B10.73B
Gross Profit19.53B19.92B19.78B20.57B26.01B
Gross Margin75.2%75.7%70.1%61.5%70.8%
Research & Development6.32B4.43B4.78B5.96B6.97B
Selling, General & Admin5.37B5.41B6.18B7.1B7.05B
Operating Expenses11.89B10.35B11.84B13.31B15.34B
Depreciation & Amortization3.4B3.42B4.07B5.59B5.17B
EBITDA11.3B12.17B14.8B13.36B16.9B
EBITDA Margin43.5%46.2%52.5%40.0%46.0%
Operating Income7.64B9.57B7.9B7.26B10.68B
Operating Margin29.4%36.3%28.0%21.7%29.1%
Interest Income00000
Interest Expense1.2B1.41B2.88B3.16B2.76B
Other Income / Expenses(938M)(2.22B)(42M)(2.65B)(1.7B)
Income Before Tax6.7B7.35B7.86B4.61B8.98B
Pre-Tax Margin25.8%27.9%27.9%13.8%24.4%
Income Tax Expense808M794M1.14B519M1.27B
Net Income5.89B6.55B6.72B4.09B7.71B
Net Margin22.7%24.9%23.8%12.2%21.0%
EPS (Basic)10.3412.1812.567.6214.33
EPS (Diluted)10.2812.1112.497.5614.23
Weighted Avg Shares570M538M535M541M538M
Weighted Avg Shares (Diluted)573M541M538M541M542M

Amgen Inc.

NASDAQ:AMGN

Intrinsic Alpha fair value

Locked

Current Price

$443.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.